{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:00:34Z","timestamp":1787760034898,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Renal anemia outcomes are influenced by sex and age; however, current guidelines for renal anemia lack sex- or age-specific standards for initiating treatment. Recently, the concept of attribute-based medicine has gained attention, with an emphasis on personalized approaches based on patient characteristics. As prognostic factors for renal and cardiovascular outcomes may vary between men and women, as well as between younger and older patients with chronic kidney disease (CKD), we aimed to investigate anemia treatment-related indicators influencing kidney disease progression and cardiovascular events across four age and sex attributes (cross-classified by sex and age\u2009&lt;\u2009or\u2009\u2265\u200965\u00a0years). A total of 1,671 patients with CKD and renal anemia from the BRIGHTEN study, who were initiated on an erythropoiesis-stimulating agent (ESA) according to Japanese guidelines for renal anemia recommending initiating treatment when the hemoglobin (Hb) level is 11\u00a0g\/dL), were analyzed using the ESA resistance index-1B (ERI-1B) and the initial ESA response index (iEResI). Baseline Hb levels were similar across all sub-groups (9.7\u20139.9\u00a0g\/dL), and kidney function was lowest in younger men (estimated glomerular filtration rate, 15.6\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>) and highest in older women (estimated glomerular filtration rate, 19.4\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>). Darbepoetin alfa doses during 12\u00a0weeks were lowest in younger men (0.79\u00a0\u03bcg\/kg) and highest in older women (1.08\u00a0\u03bcg\/kg). Renal outcomes were the poorest in younger men and the best in older women. Cardiovascular outcomes were the poorest in older men and the best in younger women. Multivariable Cox analyses showed that baseline hemoglobin levels (hazard ratio [HR], 0.77; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and the iEResI (HR, 0.76; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were associated with kidney prognosis across the cohort, whereas ERI-1B was not. When stratified by cross-classification, kidney prognosis correlated with iEResI (HR, 0.63; <jats:italic>P<\/jats:italic>\u2009=\u20090.019) in younger men and with ERI-1B (HR, 1.10; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in older women. Renal outcomes were linked to hemoglobin levels and ESA responsiveness in younger men with the poorest outcomes and to ESA resistance in older women with the best outcomes. This study revealed that renal outcomes correlated with Hb levels and ESA responsiveness in patients with CKD and anemia, especially in younger men with poor renal outcomes and with ESA resistance in older women with the best renal outcomes. Cross-classification helps identify specific patient attributes that should be targeted for optimizing anemia treatment in CKD.<\/jats:p>","DOI":"10.1038\/s41598-025-05762-y","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:08:17Z","timestamp":1751429297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Attribute based cross classification analyses from the BRIGHTEN study reveal that therapeutic responsiveness to erythropoiesis stimulating agents predicts cardiorenal prognosis in renal anemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Hiroshi","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"5762_CR1","doi-asserted-by":"crossref","unstructured":"Kent, D. M., Steyerberg, E. & van Klaveren, D. Personalized evidence based medicine: Predictive approaches to heterogeneous treatment effects. BMJ (Clinical research ed.). 363, k4245 (2018).","DOI":"10.1136\/bmj.k4245"},{"key":"5762_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6947-13-6","volume":"13","author":"JA Sacristan","year":"2013","unstructured":"Sacristan, J. A. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med. Inform. Decis. Mak. 13, 6 (2013).","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"5762_CR3","doi-asserted-by":"crossref","unstructured":"Bardes, C. L. Defining \"patient-centered medicine\". N. Engl. J. Med. 366, 782\u2013783 (2012).","DOI":"10.1056\/NEJMp1200070"},{"key":"5762_CR4","first-page":"191","volume":"6","author":"S Akhondzadeh","year":"2014","unstructured":"Akhondzadeh, S. Personalized medicine: a tailor made medicine. Avicenna J. Med. Biotechnol. 6, 191 (2014).","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"5762_CR5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.0887-378X.2004.00327.x","volume":"82","author":"RL Kravitz","year":"2004","unstructured":"Kravitz, R. L., Duan, N. & Braslow, J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 82, 661\u2013687 (2004).","journal-title":"Milbank Q."},{"key":"5762_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-11-57","volume":"11","author":"JA Sacristan","year":"2011","unstructured":"Sacristan, J. A. Exploratory trials, confirmatory observations: A new reasoning model in the era of patient-centered medicine. BMC Med. Res. Methodol. 11, 57 (2011).","journal-title":"BMC Med. Res. Methodol."},{"key":"5762_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cts.12884","volume":"14","author":"K Johnson","year":"2021","unstructured":"Johnson, K. et al. Precision medicine, AI, and the future of personalized health care. Clin. Transl. Sci. 14, 86\u201393 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"5762_CR8","doi-asserted-by":"publisher","first-page":"19155","DOI":"10.1038\/s41598-022-23882-7","volume":"12","author":"Y Ushio","year":"2022","unstructured":"Ushio, Y. et al. Machine learning for morbid glomerular hypertrophy. Sci. Rep. 12, 19155\u201319155 (2022).","journal-title":"Sci. Rep."},{"key":"5762_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12916-018-1122-7","volume":"16","author":"H Fr\u00f6hlich","year":"2018","unstructured":"Fr\u00f6hlich, H. et al. From hype to reality: Data science enabling personalized medicine. BMC Med. 16, 150\u2013150 (2018).","journal-title":"BMC Med."},{"key":"5762_CR10","doi-asserted-by":"crossref","unstructured":"Kataoka, H., Nitta, K. & Hoshino, J. Visceral fat and attribute-based medicine in chronic kidney disease. Front. Endocrinol. 14 (2023).","DOI":"10.3389\/fendo.2023.1097596"},{"key":"5762_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00041552-200003000-00001","volume":"9","author":"VD Nenov","year":"2000","unstructured":"Nenov, V. D., Taal, M. W., Sakharova, O. V. & Brenner, B. M. Multi-hit nature of chronic renal disease. Curr. Opin. Nephrol. Hypertens. 9, 85\u201397 (2000).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"5762_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000501021","volume":"44","author":"H Kataoka","year":"2019","unstructured":"Kataoka, H. et al. A body mass index-based cross-classification approach for the assessment of prognostic factors in chronic kidney disease progression. Kidney Blood Press. Res. 44, 362\u2013383 (2019).","journal-title":"Kidney Blood Press. Res."},{"key":"5762_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0140-6736(05)70156-2","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell, P. M., Mehta, Z., Howard, S. C., Gutnikov, S. A. & Warlow, C. P. Treating individuals 3: from subgroups to individuals: General principles and the example of carotid endarterectomy. Lancet 365, 256\u2013265 (2005).","journal-title":"Lancet"},{"key":"5762_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2288-15-4","volume":"15","author":"JA Sacristan","year":"2015","unstructured":"Sacristan, J. A. Clinical research and medical care: Towards effective and complete integration. BMC Med. Res. Methodol. 15, 4 (2015).","journal-title":"BMC Med. Res. Methodol."},{"key":"5762_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-023-00784-z","volume":"20","author":"NC Chesnaye","year":"2024","unstructured":"Chesnaye, N. C., Carrero, J. J., Hecking, M. & Jager, K. J. Differences in the epidemiology, management and outcomes of kidney disease in men and women. Nat. Rev. Nephrol. 20, 7\u201320 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"5762_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41581-024-00840-2","volume":"20","author":"D Mohottige","year":"2024","unstructured":"Mohottige, D., Farouk, S., Poteat, T., Radix, A. & Witchel, S. F. Considerations of sex as a binary variable in clinical algorithms. Nat. Rev. Nephrol. 20, 347\u2013348 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"5762_CR17","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1038\/s41598-022-07737-9","volume":"12","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study. Sci. Rep. 12, 3784 (2022).","journal-title":"Sci. Rep."},{"key":"5762_CR18","doi-asserted-by":"crossref","unstructured":"Kataoka, H. et al. Sex differences in time-series changes in pseudo-R2 values regarding hyperuricemia in relation to the kidney prognosis. J. Person. Med.. 10 (2020).","DOI":"10.3390\/jpm10040248"},{"key":"5762_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12072-021-10176-9","volume":"15","author":"H Kataoka","year":"2021","unstructured":"Kataoka, H. et al. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. Hep. Intl. 15, 791\u2013803 (2021).","journal-title":"Hep. Intl."},{"key":"5762_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/ajkd.2001.26842","volume":"38","author":"O Ifudu","year":"2001","unstructured":"Ifudu, O. et al. Gender modulates responsiveness to recombinant erythropoietin. Am. J. Kidney Dis. 38, 518\u2013522 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"5762_CR21","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","volume":"162","author":"BC Astor","year":"2002","unstructured":"Astor, B. C., Muntner, P., Levin, A., Eustace, J. A. & Coresh, J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988\u20131994). Arch. Intern. Med. 162, 1401\u20131408 (2002).","journal-title":"Arch. Intern. Med."},{"key":"5762_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10157-020-01856-1","volume":"24","author":"Y Ushio","year":"2020","unstructured":"Ushio, Y. et al. Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: A retrospective study. Clin. Exp. Nephrol. 24, 500\u2013508 (2020).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR23","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/ndt\/gft338","volume":"28","author":"R Minutolo","year":"2013","unstructured":"Minutolo, R. et al. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: A multicentre prospective study in renal clinics. Nephrol. Dial. Transplant. 28, 3035\u20133045 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"5762_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10157-023-02432-z","volume":"28","author":"M Nangaku","year":"2024","unstructured":"Nangaku, M., Ueta, K., Nishimura, K., Sasaki, K. & Hashimoto, T. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies. Clin. Exp. Nephrol. 28, 391\u2013403 (2024).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR25","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.ekir.2023.07.032","volume":"8","author":"M Canney","year":"2023","unstructured":"Canney, M. et al. Regional variation in hemoglobin distribution among individuals with CKD: The ISN international network of CKD cohorts. Kidney Int. Rep. 8, 2056\u20132067 (2023).","journal-title":"Kidney Int. Rep."},{"key":"5762_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","volume":"99","author":"JL Babitt","year":"2021","unstructured":"Babitt, J. L. et al. Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 99, 1280\u20131295 (2021).","journal-title":"Kidney Int."},{"key":"5762_CR27","doi-asserted-by":"crossref","unstructured":"Jin, Y. & Park, Y. An integrated approach to determining rural tourist satisfaction factors using the IPA and conjoint analysis. Int. J. Environ. Res. Public Health. 16 (2019).","DOI":"10.3390\/ijerph16203848"},{"key":"5762_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2288-6-18","volume":"6","author":"RA Hayward","year":"2006","unstructured":"Hayward, R. A., Kent, D. M., Vijan, S. & Hofer, T. P. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med. Res. Methodol. 6, 18 (2006).","journal-title":"BMC Med. Res. Methodol."},{"key":"5762_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mbs.2011.10.001","volume":"235","author":"J Glasser","year":"2012","unstructured":"Glasser, J., Feng, Z., Moylan, A., Del Valle, S. & Castillo-Chavez, C. Mixing in age-structured population models of infectious diseases. Math Biosci. 235, 1\u20137 (2012).","journal-title":"Math Biosci."},{"key":"5762_CR30","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s00380-019-01375-4","volume":"34","author":"K Kawachi","year":"2019","unstructured":"Kawachi, K., Kataoka, H., Manabe, S., Mochizuki, T. & Nitta, K. Low HDL cholesterol as a predictor of chronic kidney disease progression: A cross-classification approach and matched cohort analysis. Heart Vessels. 34, 1440\u20131455 (2019).","journal-title":"Heart Vessels."},{"key":"5762_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto, H. et al. 2015 Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. Renal Replacement Therapy. 3, 36 (2017).","journal-title":"Renal Replacement Therapy."},{"key":"5762_CR32","doi-asserted-by":"crossref","unstructured":"Singh, S. & Bajorek, B. Defining \u2018elderly\u2019 in clinical practice guidelines for pharmacotherapy. Pharm .Pract. (Granada). 12, 489 (2014).","DOI":"10.4321\/S1886-36552014000400007"},{"key":"5762_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10157-017-1427-4","volume":"22","author":"H Kato","year":"2018","unstructured":"Kato, H. et al. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial). Clin. Exp. Nephrol. 22, 78\u201384 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-020-01969-7","volume":"25","author":"T Hayashi","year":"2021","unstructured":"Hayashi, T. et al. Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. Clin. Exp. Nephrol. 25, 110\u2013119 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"5762_CR36","doi-asserted-by":"publisher","first-page":"e0277921","DOI":"10.1371\/journal.pone.0277921","volume":"17","author":"I Narita","year":"2022","unstructured":"Narita, I. et al. Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study. PLoS ONE 17, e0277921\u2013e0277921 (2022).","journal-title":"PLoS ONE"},{"key":"5762_CR37","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1111\/bph.12856","volume":"172","author":"MJ Curtis","year":"2015","unstructured":"Curtis, M. J. et al. Experimental design and analysis and their reporting: New guidance for publication in BJP. Br. J. Pharmacol. 172, 3461\u20133471 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"5762_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff, E. & McCulloch, C. E. Relaxing the rule of ten events per variable in logistic and Cox regression. Am. J. Epidemiol. 165, 710\u2013718 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"5762_CR39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","volume":"63","author":"WF Keane","year":"2003","unstructured":"Keane, W. F. et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 63, 1499\u20131507 (2003).","journal-title":"Kidney Int."},{"key":"5762_CR40","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1681\/ASN.2005030226","volume":"16","author":"P Vlagopoulos","year":"2005","unstructured":"Vlagopoulos, P. et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J. Am. Soc. Nephrol. 16, 3403\u20133410 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"5762_CR41","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10157-023-02362-w","volume":"27","author":"S Maruyama","year":"2023","unstructured":"Maruyama, S. et al. Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial. Clin. Exp. Nephrol. 27, 757\u2013766 (2023).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR42","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"M Pfeffer","year":"2009","unstructured":"Pfeffer, M. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019\u20132032 (2009).","journal-title":"N. Engl. J. Med."},{"key":"5762_CR43","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"A Singh","year":"2006","unstructured":"Singh, A. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085\u20132098 (2006).","journal-title":"N. Engl. J. Med."},{"key":"5762_CR44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"L Szczech","year":"2008","unstructured":"Szczech, L. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 74, 791\u2013798 (2008).","journal-title":"Kidney Int."},{"key":"5762_CR45","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","volume":"363","author":"S Solomon","year":"2010","unstructured":"Solomon, S. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 363, 1146\u20131155 (2010).","journal-title":"N. Engl. J. Med."},{"key":"5762_CR46","doi-asserted-by":"crossref","unstructured":"Rossert, J., Gassmann Mayer, C., Frei, D. & McClellan, W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol. Dial. Transplant. 22, 794\u2013800 (2007).","DOI":"10.1093\/ndt\/gfl716"},{"key":"5762_CR47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1744-9987.2010.00836.x","volume":"14","author":"Y Tsubakihara","year":"2010","unstructured":"Tsubakihara, Y. et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther. Apher. Dial. 14, 240\u2013275 (2010).","journal-title":"Ther. Apher. Dial."},{"key":"5762_CR48","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli, F. et al. Kidney disease: Improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol. Dial. Transplant. 28, 1346\u20131359 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"5762_CR49","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2012.270","volume":"82","author":"TB Drueke","year":"2012","unstructured":"Drueke, T. B. & Parfrey, P. S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 82, 952\u2013960 (2012).","journal-title":"Kidney Int."},{"key":"5762_CR50","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10157-014-0948-3","volume":"18","author":"K Kimura","year":"2014","unstructured":"Kimura, K. Preface: evidence-based clinical practice guidelines for CKD: An abridged English version. Clin. Exp. Nephrol. 18, 339\u2013340 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR51","doi-asserted-by":"crossref","unstructured":"Japanese Society of, N. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin. Exp. Nephrol. 23, 1\u201315 (2019).","DOI":"10.1007\/s10157-018-1648-1"},{"key":"5762_CR52","doi-asserted-by":"crossref","unstructured":"Japanese Society of, N. Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin. Exp. Nephrol. 28, 473\u2013495 (2024).","DOI":"10.1007\/s10157-024-02497-4"},{"key":"5762_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1681\/ASN.2005070757","volume":"17","author":"M Nangaku","year":"2006","unstructured":"Nangaku, M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 17, 17\u201325 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"5762_CR54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","volume":"66","author":"C Gouva","year":"2004","unstructured":"Gouva, C., Nikolopoulos, P., Ioannidis, J. P. A. & Siamopoulos, K. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 66, 753\u2013760 (2004).","journal-title":"Kidney Int."},{"key":"5762_CR55","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10157-015-1225-9","volume":"20","author":"T Akizawa","year":"2016","unstructured":"Akizawa, T. et al. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study. Clin. Exp. Nephrol. 20, 885\u2013895 (2016).","journal-title":"Clin. Exp. Nephrol."},{"key":"5762_CR56","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1744-9987.2012.01082.x","volume":"16","author":"Y Tsubakihara","year":"2012","unstructured":"Tsubakihara, Y. et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther. Apher. Dial. 16, 529\u2013540 (2012).","journal-title":"Ther. Apher. Dial."},{"key":"5762_CR57","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/ckj\/sfaa213","volume":"14","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: A nationwide study. Clin. Kidney J. 14, 1780\u20131788 (2021).","journal-title":"Clin. Kidney J."},{"key":"5762_CR58","doi-asserted-by":"publisher","first-page":"1291922","DOI":"10.3389\/fphar.2023.1291922","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang, J., Zhu, P., Li, S., Gao, Y. & Xing, Y. From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge. Front. Pharmacol. 14, 1291922 (2023).","journal-title":"Front. Pharmacol."},{"key":"5762_CR59","doi-asserted-by":"crossref","unstructured":"Zhao, B. R., Hu, X. R., Wang, W. D. & Zhou, Y. Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies. Acta Pharmacol. Sin. (2025).","DOI":"10.1038\/s41401-025-01476-z"},{"key":"5762_CR60","doi-asserted-by":"publisher","first-page":"88972","DOI":"10.5527\/wjn.v13.i1.88972","volume":"13","author":"JD Juarez-Villa","year":"2024","unstructured":"Juarez-Villa, J. D. et al. Exploring kidney biopsy findings in congenital heart diseases: Insights beyond cyanotic nephropathy. World J. Nephrol. 13, 88972 (2024).","journal-title":"World J. Nephrol."},{"key":"5762_CR61","doi-asserted-by":"publisher","first-page":"20752","DOI":"10.1038\/s41598-023-48125-1","volume":"13","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Impact of recombinant human brain natriuretic peptide on emergency dialysis and prognosis in end-stage renal disease patients with type 4 cardiorenal syndrome. Sci. Rep. 13, 20752 (2023).","journal-title":"Sci. Rep."},{"key":"5762_CR62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5527\/wjn.v12.i5.182","volume":"12","author":"S Taheri","year":"2023","unstructured":"Taheri, S. Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis. World J. Nephrol. 12, 182\u2013200 (2023).","journal-title":"World J. Nephrol."},{"key":"5762_CR63","doi-asserted-by":"publisher","first-page":"18732","DOI":"10.1038\/s41598-024-69662-3","volume":"14","author":"B Zhou","year":"2024","unstructured":"Zhou, B., Zhao, J. & Li, D. A new animal model of cardiorenal syndrome could be established by inducing heart failure through coronary artery ligation in spontaneously hypertensive rats. Sci. Rep. 14, 18732 (2024).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05762-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:15:53Z","timestamp":1751436953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5762"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05762-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Conducted within Japan\u2019s healthcare framework, the BRIGHTEN study adhered to the Declaration of Helsinki and Japan\u2019s Ethical Guidelines on Clinical Studies. Participants provided written informed consent, and the protocol was approved by the review boards of Nagoya University (approval number: 2014-0027) and its related facilities (Niigata University, 2023\u20130014; Tokyo Women\u2019s Medical University, C23-043).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"23221"}}